A case ofnon-cirrhotic portal hypertension in a patient with systemic lupus erythematosus, the first to our knowledge, is described. Severe pulmonary hypertension was associated with the portal hypertension and with markers of active auto-immunity. Pulmonary hypertension has not previously been associated with non-cirrhotic portal hypertension. The coexistence of vasculopathy of the portal and pulmonary vascular beds in this patient with active autoimmunity supports the postulate that portal-pulmonary hypertension may be immunologically mediated.
Introduction
Although liver disease occurs in up to 20% of patients with systemic lupus erythematosus (SLE),' non-cirrhotic portal hypertension (NCPH), characterized histologically by portal fibrosis and obliterative lesions of the terminal hepatic veins but well-maintained hepatic architecture,2'3 has not, to the best of our knowledge, previously been documented in SLE. The frequency of primary pulmonary hypertension in patients with portal hypertension is at least 2%,4 which is many times greater than the prevalence in the general population. Pulmonary hypertension has been associated with cirrhosis and portal vein thrombosis, but has not previously been documented in a case of non-cirrhotic portal hypertension.5 The cause of the pulmonary hypertension associated with portal hypertension remains obscure but an association with autoimmune phenomena has been suggested. 6 The case presented documents portal and pulmonary hypertension in a patient with markers of active autoimmunity but absent lupus anticoagulant and supports the postulate that autoimmunity may play a role in inducing the pulmonary hypertension found in patients with portal hypertension. 404 (normal 0-50 U/1), but serum aspartate and alanine transferase activities were normal. Hepatitis B was negative and alpha-I antitrypsin, copper and iron studies were normal. Liver histology showed typical changes of non-cirrhotic portal hypertension (Figure 1 ).
Discussion
Cirrhosis, chronic active hepatitis, granulomatous hepatitis, chronic persistent hepatitis' and focal nodular hyperplasia8 have been found in up to 20% of patients with SLE. We have been unable to find any previous description of non-cirrhotic portal hypertension in SLE which should be considered in patients who have little hepatocellular dysfunction but evidence of portal hypertension or ascites.
Primary pulmonary hypertension occurs markedly more frequently in patients with portal hypertension.4 Although in most reported cases of portal-pulmonary hypertension, the portal abnormality is demonstrated before the pulmonary hypertension, several cases have been documented where recognition of the pulmonary hypertension preceded that of the portal hypertension.4'9"0 As both pulmonary and portal hypertension may be clinically silent, abnormalities of both portal and pulmonary vascular beds may be present for con--'VV~~~~~~~. siderable periods before being recognized.
The mechanism of the pulmonary hypertension associated with portal hypertension remains obscure. Primary pulmonary hypertension may occur in systemic lupus erythematosus but is usually associated with the lupus anticoagulant" which was not detected in this case. A total of 5 -10% of patients with portal-pulmonary hypertension have some evidence of autoimmune activity or an associated autoimmune disease.5'6 The aetiology of the portal vasculopathy in non-cirrhotic portal hypertension may also be immunologically mediated, as impaired cell-mediated immunity" and disturbed T4/T8 lymphocyte ratios1 have been demonstrated in these patients. In this patient, the active rash, complement consumption and high levels of circulating immune complexes indicated an active autoimmune process. This case supports the postulate that the pulmonary hypertension associated with portal hypertension may be immunologically mediated. 
